; (ii) the development of resistance to each drug for which an exclusivity extension period was awarded under subsection (a); (iii) the private and societal value of each drug for which an exclusivity extension period was awarded under subsection (a); and (iv) the impact on patients and public and private markets of the recipient drug with respect to which a conveyed exclusivity extension period was used. (C) Report Not later than 1 year after the date by which the study under subparagraph (A) is required to begin under subparagraph (A), the Director of the Centers for Disease Control and Prevention and Comptroller General shall submit to the Congress a report containing the results of the study. (2) Study by GAO Not later than the date that is 5 years after the date of the first award under subsection (a), the Comptroller General of the United States shall— (A) complete a study on the actual and projected impacts of the program under this section on Federal expenditures; and (B) submit a report on the results of such study to the Congress. (o) Report on reauthorization Not later than 180 days after the Secretary awards the ninth exclusivity extension period under this section, the Committee shall submit a report to the Secretary and the Congress containing recommendations on the reauthorization of this section, including recommendations on increasing the number of awards allowed by subsection (g)(1). (p) Definitions In this section: (1) The term biological product has the meaning given to such term in section 351(i) of the Public Health Service Act. (2) The term Committee means the Committee on Developing Critical Need Antimicrobials established under subsection (j). (3) The term conveyed exclusivity extension period means an exclusivity extension period conveyed pursuant to subsection (a). (4) The term priority antimicrobial product means a product that is designated under subsection (k). (5) The term recipient drug means a drug approved under section 505 receiving a conveyed exclusivity extension period. .